TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive") (TSX-V:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, and Ehave, Inc. (“Ehave”) (OTCQB:EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, are pleased to announce that they have entered into a collaboration agreement to enable enhanced patient and clinical research data management for Revive’s research initiatives involving medical cannabis for the treatment of liver diseases.



The collaboration agreement will leverage Ehave’s core expertise in health informatics through its Ehave Connect platform. Revive will integrate the Ehave Connect solution of diagnostic and treatment tools with its ongoing research initiatives in liver disease to improve the lives of patients. Ehave Connect will collect and integrate patient data from clinical systems, licensed health surveys, and Ehave’s own patient- and clinician-reported outcome applications, empowering users with an end-to-end patient management solution, allowing for better treatment decisions across teams and disciplines while keeping patients informed and engaged throughout their healthcare journey.

“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Craig Leon, Chief Executive Officer of Revive. “Ehave’s Platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research and may provide unique insights to expand our initiatives with cannabinoids for the potential treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.”

“Our collaboration with Revive is an important step toward realizing Ehave’s broader goal of partnering with the healthcare community, and in particular companies advancing novel medical cannabis products, to facilitate clinical trials and patient management with a single easy-to-use, end-to-end data informatics platform,” stated Prateek Dwivedi, President and CEO of Ehave. “Not only will this collaboration help to streamline Revive’s research and clinical programs, but it also stands to further establish Ehave’s position as a leader in the health informatics space.”

About Ehave, Inc.

Ehave, Inc. (OTCQB: EHVVF) is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave's mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems ("MHS"), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder ("ADHD"), through its collaboration with the Hospital for Sick Children ("SickKids"). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. For more information, visit www.ehave.com.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV)(OTCQB:RVVTF) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid-based pharmaceutical markets. Additional information on Revive is available at www.ReviveThera.com

Ehave, Inc. Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

Revive Therapeutics Ltd. Cautionary Note Regarding Forward-Looking Statements

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking information" that involves known and unknown risks and uncertainties, which are not comprised of historical facts, and most of which are beyond the control of Revive. Forward-looking statements include estimates and statements that describe Revive’s future plans, objectives or goals, including words to the effect that Revive or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company’s research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect and no assurance can be given that such events will occur in the disclosed time frames or at all.

Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2017 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Contact:

For Ehave, Inc.

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (Investors)

(212) 375-2664

jdrumm@tiberend.com

Janine McCargo (Media)

646-604-5150

jmccargo@tiberend.com

For Revive Therapeutics Ltd.

Craig Leon

Chief Executive Officer

Revive Therapeutics Ltd.

Tel: (416) 272-5525

Email: craig@revivethera.com

Website: www.revivethera.com